Form 4: CG Oncology Executive Acquires Stock Options
SEC Form 4 Filing
Joshua F. Patterson, General Counsel and Chief Compliance Officer of CG Oncology, Inc., reports the acquisition of employee stock options.
Summary
- Joshua F. Patterson, General Counsel and Chief Compliance Officer of CG Oncology, Inc., filed a Form 4.
- The form reports the acquisition of 119,922 employee stock options with an exercise price of $20.11.
- The options were granted on April 15, 2025, and expire on April 14, 2035.
- The options vest monthly, with 1/48th of the shares vesting each month following the grant date, contingent upon continuous service.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather reports a transaction.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.
Stakeholder Impact
- The acquisition of stock options by a company officer can align their interests with those of shareholders, potentially incentivizing them to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 04/15/2025 | Date of earliest transaction (grant date of stock options) and vesting commencement date. |
| 04/14/2035 | Expiration date of the stock options. |
| 04/16/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, CG Oncology, Stock Options, Beneficial Ownership, Insider Trading, Equity Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.